Alcon annual debt-to-ebitda ratio
2008
2009
2010
2018
2019
2020
2021
2022
2023
2024
2025
Alcon Debt-to-EBITDA Ratio Growth & History (ALC)
Alcon's debt-to-ebitda ratio was 2.95 for fiscal 2025.
View full Alcon company overviewAlcon annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.95 | 0.10 | +3.67% |
| 2024 | 2024-12-31 | 2.85 | 0.48 | +20.05% |
| 2023 | 2023-12-31 | 2.37 | −0.70 | −22.69% |
| 2022 | 2022-12-31 | 3.07 | 0.06 | +2.12% |
| 2021 | 2021-12-31 | 3.00 | −2.06 | −40.68% |
| 2020 | 2020-12-31 | 5.07 | 1.78 | +54.34% |
| 2019 | 2019-12-31 | 3.28 | 3.15 | +2337.21% |
| 2018 | 2018-12-31 | 0.13 | — | — |
| 2010 | 2010-12-31 | 0.15 | −0.12 | −45.69% |
| 2009 | 2009-12-31 | 0.27 | −0.20 | −42.53% |
| 2008 | 2008-12-31 | 0.47 | — | — |
Alcon quarterly debt-to-ebitda ratio
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.94 | — | — |
| Q1 2026 | 2026-03-31 | 2.07 | — | — |
| Q4 2025 | 2025-12-31 | 1.94 | — | — |
| Q4 2010 | 2010-12-31 | 0.15 | −0.12 | −45.69% |
| Q3 2010 | 2010-09-30 | 0.13 | — | — |
| Q2 2010 | 2010-06-30 | 0.13 | — | — |
| Q1 2010 | 2010-03-31 | 0.27 | — | — |
| Q4 2009 | 2009-12-31 | 0.27 | — | — |
Alcon debt-to-ebitda ratio trends
Over the last five fiscal years, Alcon's debt-to-ebitda ratio decreased from 5.07 to 2.95, a change of −2.11. The latest reported quarter, Q2 2026, shows 1.94.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alcon source filings ↗Community posts
Alcon completes $550 million Neurotech acquisition to enter MacTel treatment
Alcon ($ALC) has acquired Neurotech for $550 million, with additional payments dependent on commercial milestones. The transaction adds ENCELTO, a cell-based ocular therapy for adults with macular telangiectasia type 2. The product received ...
